Argent BioPharma Balance Sheet Health
Financial Health criteria checks 3/6
Argent BioPharma has a total shareholder equity of A$671.7K and total debt of A$9.2M, which brings its debt-to-equity ratio to 1366.5%. Its total assets and total liabilities are A$17.3M and A$16.7M respectively.
Key information
1,366.5%
Debt to equity ratio
AU$9.18m
Debt
Interest coverage ratio | n/a |
Cash | AU$6.48m |
Equity | AU$671.75k |
Total liabilities | AU$16.66m |
Total assets | AU$17.33m |
Recent financial health updates
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Jun 23MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Mar 09Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)
Oct 08Recent updates
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Jun 23MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Mar 09Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)
Oct 08If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns
Feb 21What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?
Dec 30Financial Position Analysis
Short Term Liabilities: RGT's short term assets (A$9.4M) do not cover its short term liabilities (A$12.4M).
Long Term Liabilities: RGT's short term assets (A$9.4M) exceed its long term liabilities (A$4.3M).
Debt to Equity History and Analysis
Debt Level: RGT's net debt to equity ratio (401.5%) is considered high.
Reducing Debt: RGT's debt to equity ratio has increased from 0.2% to 1366.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RGT has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: RGT is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.